Rapamycin (Sirolimus) Complete Drug-Drug Interaction Profile

How Sirolimus Works: The mTOR Mechanism Behind Its Interactions

Sirolimus binds the intracellular protein FKBP-12, and the resulting complex inhibits the mechanistic target of rapamycin (mTOR), a serine/threonine kinase that regulates cell growth, proliferation, and immune activation. This is the same binding protein targeted by tacrolimus, though the downstream pathway diverges completely. Tacrolimus-FKBP-12 inhibits calcineurin; sirolimus-FKBP-12 inhibits mTOR complex 1 (mTORC1).

The pharmacokinetic profile of sirolimus creates its interaction vulnerability. Oral bioavailability sits at roughly 14% due to extensive first-pass metabolism by CYP3A4 in the gut wall and liver, combined with active efflux by P-glycoprotein back into the intestinal lumen 1. The mean terminal half-life is 62 hours in stable renal transplant patients, meaning interaction effects persist for days after the offending agent is started or stopped. Sirolimus distributes extensively into red blood cells, with a blood-to-plasma ratio of approximately 36, which is why whole-blood trough monitoring (not plasma) is the standard assay 1.

Any drug that inhibits or induces CYP3A4, blocks or upregulates P-gp, or competes for FKBP-12 binding has the potential to alter sirolimus exposure. The narrow therapeutic index (trough targets typically 4 to 12 ng/mL for transplant) means even modest changes in blood concentration can trigger toxicity or graft rejection.

CYP3A4 Inhibitors: The Most Dangerous Category

Strong CYP3A4 inhibitors produce the largest magnitude increases in sirolimus exposure, and co-prescribing without dose adjustment is considered a prescribing error in transplant medicine. The FDA label quantifies the ketoconazole interaction precisely: a single 10 mg dose of sirolimus oral solution given with ketoconazole 200 mg twice daily for 10 days increased sirolimus Cmax by 4.3-fold and AUC by 10.9-fold 1.

Other strong CYP3A4 inhibitors that require the same vigilance include itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, and HIV protease inhibitors (ritonavir, nelfinavir). Voriconazole is particularly relevant in transplant populations prone to fungal infections. The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) transplant guidelines specifically recommend therapeutic drug monitoring whenever azole antifungals are started or stopped in patients on mTOR inhibitors 2.

Moderate CYP3A4 inhibitors also produce clinically meaningful changes. Erythromycin, fluconazole, diltiazem, and verapamil each raise sirolimus trough concentrations enough to warrant monitoring. Diltiazem 120 mg daily increased sirolimus AUC by 60% and Cmax by 43% in healthy volunteers 1. For clinicians managing off-label longevity protocols, this matters: patients on calcium channel blockers for hypertension may unknowingly amplify their weekly rapamycin dose.

Grapefruit juice inhibits intestinal CYP3A4 and should be avoided entirely. The FDA label does not quantify the magnitude, but the interaction is listed as clinically significant, and the Rapamune prescribing information instructs patients to take sirolimus consistently with or without food but never with grapefruit juice 1.

CYP3A4 Inducers: The Silent Efficacy Killers

CYP3A4 inducers reduce sirolimus blood levels, sometimes dramatically enough to cause acute rejection in transplant patients or render a longevity dose pharmacologically inert. Rifampin is the index case. Co-administration of rifampin 600 mg daily for 14 days with a single 10 mg sirolimus dose decreased sirolimus AUC by approximately 82% and Cmax by 71% 1.

Other potent CYP3A4 inducers with similar expected effects include rifabutin, phenytoin, carbamazepine, phenobarbital, and St. John's wort. St. John's wort deserves special emphasis because patients pursuing off-label rapamycin for longevity often self-prescribe herbal supplements without disclosing them. A 2014 systematic review in Clinical Pharmacology and Therapeutics confirmed that hyperforin in St. John's wort is among the most potent known CYP3A4 inducers, with effects comparable to rifampin for several substrate drugs 3.

The clinical response to inducers should follow a standard algorithm: increase monitoring frequency (weekly trough levels for 2 to 4 weeks after starting or stopping the inducer), adjust the sirolimus dose upward as guided by troughs, and reassess once the inducer reaches steady-state induction (typically 10 to 14 days for rifampin).

The Cyclosporine-Sirolimus Interaction: Timing Is Everything

Cyclosporine and sirolimus are frequently co-prescribed in renal transplant protocols. Their interaction is bidirectional and dose-timing dependent. Cyclosporine inhibits both CYP3A4 and P-gp, and when sirolimus is given simultaneously with cyclosporine, sirolimus Cmax increases by 116% and AUC increases by 80% compared to sirolimus given alone 1.

The FDA-approved dosing strategy is to administer sirolimus 4 hours after cyclosporine. This separation reduces the magnitude of the interaction because cyclosporine's inhibition of intestinal CYP3A4 and P-gp is greatest when drug concentrations in the gut are highest (around the time of cyclosporine dosing). Even with 4-hour separation, sirolimus levels remain higher than they would be without cyclosporine, so the interaction is attenuated but not eliminated 1.

Clinicians transitioning patients from cyclosporine-based to cyclosporine-free regimens should expect sirolimus trough levels to drop by 30 to 50% once cyclosporine is fully cleared. The KDIGO guidelines recommend measuring sirolimus troughs 1 to 2 weeks after cyclosporine withdrawal and adjusting the sirolimus dose upward to maintain target exposure 2.

Tacrolimus and Other Calcineurin Inhibitors

Tacrolimus and sirolimus compete for FKBP-12 binding, though their downstream targets differ. Co-administration is used in some transplant centers, but the combination amplifies shared toxicities, particularly nephrotoxicity and hyperlipidemia. A 2004 analysis published in the American Journal of Transplantation found that sirolimus-tacrolimus combinations produced higher rates of new-onset diabetes mellitus after transplantation compared to tacrolimus-mycophenolate regimens 4.

The pharmacokinetic interaction between tacrolimus and sirolimus is less well quantified than the cyclosporine-sirolimus interaction, but both are CYP3A4 substrates and P-gp substrates. Co-prescription requires monitoring of both drug troughs and often necessitates dose reductions of one or both agents. The Endocrine Society's clinical practice guidelines on post-transplant diabetes recommend screening glucose more frequently when these drugs are combined 5.

Statins and Lipid-Lowering Agents

Sirolimus causes dose-dependent hyperlipidemia. In the key transplant trials, 38 to 57% of patients on sirolimus-cyclosporine-steroid regimens required lipid-lowering therapy by 24 months 1. This makes statin co-prescription near-universal in transplant patients and increasingly relevant in longevity protocols.

The interaction risk is indirect but real. Sirolimus itself does not significantly inhibit CYP3A4, but many statins (simvastatin, atorvastatin, lovastatin) are CYP3A4 substrates. In patients already on a CYP3A4 inhibitor like cyclosporine, adding sirolimus to a statin-containing regimen compounds the overall CYP3A4 inhibition burden. The FDA label for simvastatin specifically contraindicates doses above 10 mg daily when co-administered with cyclosporine 6.

Pravastatin, rosuvastatin, and pitavastatin are preferred in transplant populations because they are not primarily CYP3A4 substrates. For patients on off-label rapamycin without cyclosporine, the statin interaction risk from sirolimus alone is low, but lipid monitoring every 3 to 6 months remains good practice.

Vaccines and Immunosuppression Considerations

Sirolimus suppresses T-cell and B-cell proliferation through mTOR inhibition, which impairs vaccine responses. Live vaccines (MMR, varicella, yellow fever, live-attenuated influenza) are contraindicated during sirolimus therapy, consistent with CDC guidance for immunosuppressed patients 7.

The picture for inactivated vaccines is more complex. The PEARL trial (N=40 healthy adults aged 55 to 85, Aging Cell 2024) used low-dose rapamycin (0.5 or 1 mg daily, 8 weeks on / 2 weeks off cycling) and evaluated immune function as a secondary endpoint. The trial found that low-dose rapamycin did not impair influenza vaccine antibody titers compared to placebo in this small, healthy cohort 8. An earlier trial by Mannick et al. (2014, Science Translational Medicine, N=218) demonstrated that the mTOR inhibitor everolimus (a rapamycin analogue) at low doses actually improved influenza vaccine response in elderly subjects by approximately 20% 9.

These findings suggest a dose-dependent bifurcation: transplant-level sirolimus (trough 4 to 12 ng/mL) impairs vaccine responses, while low-dose intermittent rapamycin (sub-therapeutic troughs) may preserve or even enhance them. The distinction matters for longevity prescribers scheduling vaccinations.

Antifungals, Antibiotics, and Anti-Infectives

Transplant and immunosuppressed patients frequently require anti-infective therapy. The interaction profile with this drug class is dense.

Azole antifungals are the highest-risk group. Ketoconazole (10.9-fold AUC increase), itraconazole, voriconazole, and posaconazole all produce clinically dangerous elevations. Fluconazole, a moderate inhibitor, raises sirolimus levels enough to require monitoring but rarely requires holding sirolimus entirely 1. The Infectious Diseases Society of America (IDSA) guidelines for invasive candidiasis recommend echinocandins (caspofungin, micafungin, anidulafungin) as first-line therapy in transplant patients on mTOR inhibitors specifically to avoid the azole-sirolimus interaction 10.

Macrolide antibiotics present a graded risk. Clarithromycin is a strong CYP3A4 inhibitor and should be avoided or require aggressive monitoring. Erythromycin is moderate. Azithromycin has minimal CYP3A4 inhibition and is the preferred macrolide in sirolimus-treated patients.

Rifamycins (rifampin, rifabutin) are potent inducers and may render sirolimus sub-therapeutic within days. If rifampin is essential (e.g., active tuberculosis), sirolimus doses may need to increase 3-fold or more, with twice-weekly trough monitoring until stable 1.

Interactions Relevant to Off-Label Longevity Dosing

Patients taking rapamycin off-label for longevity (typically 3 to 6 mg once weekly) face a different interaction profile than transplant patients on daily dosing. The intermittent dosing produces transient mTORC1 inhibition followed by a washout period, and drug-interaction effects are concentrated around the dosing day.

Practical implications for common co-medications in the longevity population:

Metformin. No direct pharmacokinetic interaction. Metformin is renally cleared and does not involve CYP3A4 or P-gp. The combination is pharmacologically rational because both target overlapping aging pathways (mTOR and AMPK), though no randomized trial has tested the combination specifically for longevity endpoints 11.

GLP-1 receptor agonists (semaglutide, tirzepatide). No known CYP3A4 interaction. GLP-1 RAs are peptides cleared by proteolytic degradation, not hepatic metabolism. The main concern is additive gastrointestinal side effects (nausea, diarrhea) if rapamycin is taken on the same day as a GLP-1 injection.

Testosterone (TRT). Testosterone cypionate and enanthate are CYP3A4 substrates at the metabolic level, but intramuscular dosing bypasses first-pass metabolism. The interaction risk with sirolimus is minimal for injectable testosterone. Oral testosterone undecanoate (Jatenzo), which does undergo intestinal CYP3A4 metabolism, may have a theoretical bidirectional interaction with sirolimus, though no clinical data exist 1.

NAD+ precursors (NMN, NR). No known CYP3A4 or P-gp involvement. No interaction expected.

Acarbose. No direct pharmacokinetic interaction. Acarbose acts locally in the gut and has negligible systemic absorption.

Monitoring Framework for Sirolimus Drug Interactions

Every patient starting or stopping a medication while on sirolimus should have a trough level drawn 5 to 7 days after the change, regardless of whether the new drug is a known CYP3A4 interactor. This conservative approach accounts for the reality that interaction databases are incomplete and individual variability in CYP3A4 expression is wide (up to 40-fold between patients) 12.

The American Society of Transplantation (AST) recommends checking sirolimus troughs at baseline, 1 week after any medication change, and monthly during stable therapy. For off-label longevity patients on weekly dosing, trough levels should be drawn 24 hours after the weekly dose (not at the pre-dose nadir) because weekly dosing pharmacokinetics differ from daily steady-state models 2.

Signs of supratherapeutic sirolimus exposure include oral ulcers (aphthous stomatitis), new-onset hyperlipidemia, thrombocytopenia (platelet count <100,000/μL), and lower-extremity edema. Oral ulcers are the most common early signal in low-dose protocols and should prompt immediate trough measurement.